相似文献
1
A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity.
Semin Immunol. 2010 Apr;22(2):87-96. doi: 10.1016/j.smim.2009.11.001. Epub 2009 Dec 4.
2
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
Clin Immunol. 2011 Aug;140(2):142-51. doi: 10.1016/j.clim.2010.11.009. Epub 2010 Dec 24.
3
The role of invariant NKT cells at the interface of innate and adaptive immunity.
Semin Immunol. 2010 Apr;22(2):59-60. doi: 10.1016/j.smim.2010.01.002. Epub 2010 Feb 20.
4
CD1d-Restricted Natural Killer T Cells Are Preserved in Indian Long-Term Nonprogressors.
J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):e104-e112. doi: 10.1097/QAI.0000000000001322.
5
NKT-cell glycolipid agonist as adjuvant in synthetic vaccine.
Carbohydr Res. 2017 Nov 27;452:78-90. doi: 10.1016/j.carres.2017.10.006. Epub 2017 Oct 17.
6
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection.
Eur J Immunol. 2009 Mar;39(3):902-11. doi: 10.1002/eji.200838780.
7
Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
J Vis Exp. 2007(10):635. doi: 10.3791/635. Epub 2007 Dec 31.
8
NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection.
Scand J Immunol. 2011 Feb;73(2):141-6. doi: 10.1111/j.1365-3083.2010.02484.x.
9
Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Front Immunol. 2018 Jun 6;9:1266. doi: 10.3389/fimmu.2018.01266. eCollection 2018.
10
Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut.
Front Immunol. 2018 Sep 11;9:2082. doi: 10.3389/fimmu.2018.02082. eCollection 2018.
引用本文的文献
1
Five decades of clinical assessment of whole-sporozoite malaria vaccines.
Front Immunol. 2022 Sep 8;13:977472. doi: 10.3389/fimmu.2022.977472. eCollection 2022.
2
Functional Invariant Natural Killer T Cells Secreting Cytokines Are Associated With Non-Progressive Human Immunodeficiency Virus-1 Infection but Not With Suppressive Anti-Retroviral Treatment.
Front Immunol. 2018 May 24;9:1152. doi: 10.3389/fimmu.2018.01152. eCollection 2018.
3
CD3CD4CD8 (double negative) T lymphocytes and NKT cells as the main cytotoxic-related-CD107a cells in lesions of cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
Parasit Vectors. 2017 May 3;10(1):219. doi: 10.1186/s13071-017-2152-2.
4
Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(-) subsets.
Clin Exp Immunol. 2013 Apr;172(1):129-37. doi: 10.1111/cei.12045.
5
Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions.
Nat Rev Immunol. 2013 Feb;13(2):101-17. doi: 10.1038/nri3369. Epub 2013 Jan 21.
6
NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection.
Scand J Immunol. 2011 Feb;73(2):141-6. doi: 10.1111/j.1365-3083.2010.02484.x.
7
Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
Clin Immunol. 2011 Aug;140(2):142-51. doi: 10.1016/j.clim.2010.11.009. Epub 2010 Dec 24.
8
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.
Clin Immunol. 2011 Aug;140(2):119-29. doi: 10.1016/j.clim.2010.10.005. Epub 2010 Nov 20.
9
Impairment of CD1d-restricted natural killer T cells in chronic HIV type 1 clade C infection.
AIDS Res Hum Retroviruses. 2011 May;27(5):501-9. doi: 10.1089/AID.2010.0237. Epub 2010 Dec 13.
本文引用的文献
1
Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.
J Immunol. 2009 Oct 1;183(7):4415-21. doi: 10.4049/jimmunol.0901021. Epub 2009 Sep 4.
2
Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin.
J Immunol. 2009 Aug 1;183(3):1644-56. doi: 10.4049/jimmunol.0900858.
3
Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression.
AIDS. 2009 Sep 24;23(15):1965-70. doi: 10.1097/QAD.0b013e32832b5134.
4
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.
Vaccine. 2009 Jun 8;27(28):3766-74. doi: 10.1016/j.vaccine.2009.03.090. Epub 2009 Apr 23.
5
The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
J Immunol. 2009 May 15;182(10):6435-43. doi: 10.4049/jimmunol.0900136.
6
CD1d activation and blockade: a new antitumor strategy.
J Immunol. 2009 Mar 15;182(6):3366-71. doi: 10.4049/jimmunol.0802964.
7
A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
J Immunol. 2009 Feb 15;182(4):2492-501. doi: 10.4049/jimmunol.0800126.
8
Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.
Vaccine. 2009 May 26;27(25-26):3335-41. doi: 10.1016/j.vaccine.2009.01.083. Epub 2009 Feb 5.
9
Natural killer T cells and autoimmune disease.
Curr Mol Med. 2009 Feb;9(1):4-14. doi: 10.2174/156652409787314534.
10
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection.
Eur J Immunol. 2009 Mar;39(3):902-11. doi: 10.1002/eji.200838780.
Zotero 插件